20 May 2013
Keywords: mabthera, track, first-line, use, nhl, european, union
Article | 05 July 2004
The European Union's Committee for Human Medicinal Products has issued apositive opinion for the first-line use of Roche's MabThera (Rituxan;
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 June 2004
14 June 2004
19 July 2004
© 2013 thepharmaletter.com